NasdaqGS - Delayed Quote • USD
Cytokinetics, Incorporated (CYTK)
At close: 4:00 PM EDT
After hours: 4:23 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 15 |
| Avg. Estimate | -1.13 | -1.08 | -4.47 | -3.57 |
| Low Estimate | -1.36 | -1.35 | -5.42 | -5 |
| High Estimate | -0.82 | -0.66 | -3.43 | -2.18 |
| Year Ago EPS | -1.34 | -1.35 | -5.45 | -4.47 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 15 | 14 |
| Avg. Estimate | 880k | 910k | 6.35M | 142.36M |
| Low Estimate | -- | -- | -- | 5M |
| High Estimate | 1.3M | 1.38M | 44.56M | 394.65M |
| Year Ago Sales | 5.8M | 378k | 7.53M | 6.35M |
| Sales Growth (year/est) | -84.80% | 140.70% | -15.70% | 2,141.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.15 | -0.74 | -0.97 | -1.14 |
| EPS Actual | -1.34 | -1.35 | -1.38 | -1.33 |
| Difference | -0.19 | -0.61 | -0.41 | -0.19 |
| Surprise % | -16.50% | -82.40% | -42.30% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.13 | -1.08 | -4.47 | -3.57 |
| 7 Days Ago | -1.12 | -1.08 | -4.45 | -3.38 |
| 30 Days Ago | -1.12 | -1.08 | -4.45 | -3.3 |
| 60 Days Ago | -1.12 | -1.08 | -4.45 | -3.36 |
| 90 Days Ago | -1.02 | -1.06 | -4.53 | -3.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CYTK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 15.70% | -- | -- | 8.60% |
| Next Qtr. | 20.00% | -- | -- | 11.90% |
| Current Year | 18.00% | -- | -- | 5.60% |
| Next Year | 20.10% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/9/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 5/9/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/9/2024 |
| Reiterates | Needham: Buy to Buy | 5/9/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
Related Tickers
BBIO BridgeBio Pharma, Inc.
28.73
+3.72%
CLRB Cellectar Biosciences, Inc.
3.2400
+1.25%
KRYS Krystal Biotech, Inc.
158.74
+0.67%
MDGL Madrigal Pharmaceuticals, Inc.
206.92
-0.54%
BPMC Blueprint Medicines Corporation
108.34
-0.40%
APLS Apellis Pharmaceuticals, Inc.
42.52
+0.52%
BHVN Biohaven Ltd.
41.36
+1.42%
JANX Janux Therapeutics, Inc.
51.94
-6.19%
SWTX SpringWorks Therapeutics, Inc.
42.95
+1.63%
IMVT Immunovant, Inc.
29.70
-0.20%